We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current MAAT market cap is 91.77M. The company's latest EPS is EUR -1.6974 and P/E is -4.63.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.23M | 0 | 972k | 1.43M | 2.23M |
| Operating Income | -4.97M | -5.25M | -8.89M | -13.56M | -19.94M |
| Net Income | -5.84M | -5.3M | -9.02M | -13.71M | -19.72M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 8.17M | 24.28M | 49.42M | 44.73M | 42.93M |
| Total Liabilities | 12.73M | 8.34M | 9.56M | 17.92M | 22.46M |
| Total Equity | -4.56M | 15.94M | 39.86M | 26.81M | 20.47M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -5.02M | -5.84M | -7.93M | -12.61M | -18.67M |
| Investing | -154k | -494k | -238k | -815k | -440k |
| Financing | 6.98M | 20.84M | 31.56M | 5.36M | 8.14M |
| Market Cap | 91.77M |
| Price to Earnings Ratio | -4.63 |
| Price to Sales Ratio | 40.98 |
| Price to Cash Ratio | 3.76 |
| Price to Book Ratio | 4.46 |
| Dividend Yield | - |
| Shares Outstanding | 11.62M |
| Average Volume (1 week) | 2.24k |
| Average Volume (1 Month) | 3.11k |
| 52 Week Change | 11.27% |
| 52 Week High | 9.90 |
| 52 Week Low | 6.30 |
| Spread (Intraday) | 0.02 (0.25%) |
| Company Name | Maat Pharma SA |
| Address |
70 avenue tony garnier lyon, rhone 69007 |
| Website | https://www.maatpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
